Citations

Clear

815 citation(s) found for "Tang, Yu".

Mesenchymal stem cells protect renal tubular cells via TSG-6 regulating macrophage function and phenotype switching
Zhao, Yu , Zhu, Xiang-Yang, Song, Turun , Zhang, Lei , Eirin, Alfonso , Conley, Sabena M., Tang, Hui , Saadiq, Ishran M. , Jordan, Kyra L., Lerman, Lilach O. , Conley, Sabena, Saadiq, Ishran, Jordan, Kyra, Lerman, Lilach O , Eirin, Alfonso , Lerman, Amir

Mayo Clinic

American Journal of Physiology-Renal Physiology | February 8, 2021 | Volume: 320 | Issue: 3 | Pages: F454-F463

10.1152/ajprenal.00426.2020 | PMID 33554782 Get It

Tumor necrosis factor-α-induced gene/protein (TSG)-6 regulates the immunomodulatory properties of MSCs, but its ability to protect the ischemic kidney is unknown. In pigs with renal artery stenosis, we show that MSC delivery increased renal vein TSG-6, decreased kidney inflammatory macrophages, and improved renal function. In vitro, TSG-6 decreased inflammatory macrophages and tubular cell injury. Therefore, TSG-6 released from MSCs may decrease renal tubular cell injury, which is associated with regulating macrophage function and phenotype.
Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).
Dika, Imane H. El, Geyer, Susan M. , Innocenti, Federico , Yaqubie, Amin , Lopez, Juan C., Huang, Binhui , Wen, Yujia , Schwartz, Lawrence H., Nixon, Andrew B. , Shi, Qian , Jacobson, Sawyer , Tang, Yi‐Wei , Bertagnolli, Monica M. , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M. , Venook, Alan P. , Abou‐Alfa, Ghassan K.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: 325-325

10.1200/jco.2021.39.3_suppl.325 Get It

325 Background: Alliance/CALGB 80802 randomized phase III trial evaluated DO+S vs. S in pts with aHCC, and showed no improvement in median OS. Multi-drug resistant pathway mitigation by the Ras/Raf/MEK/ERK pathway and bFGF-mediated activation of Raf-1 promotes the formation of antiapoptotic Raf-1 and ASK1 complex, induced by anthracyclines. S efficiently blocks NS5A-recruited c-Raf mediated HCV replication and viral gene expression. Once inhibited by S, VEGF expression of HepG2 may limit HCV cellular entry. Release of Raf-1-Ask-1 dimer and inhibition of Raf-1 via S putatively differ in the presence or absence of DO. We hypothesize treatment with S reduces HCV titer levels (TL) and influence pts’ outcome. Methods: In 80802 HCV pts, TL were evaluated in both arms at baseline and post-baseline at Day 1 of Cycles 2, 3, and every 2 cycles and at progression or discontinuation of therapy. HCV undetectable (HCV-UN) levels were defined as < 50 copies/mL. TL were evaluated in relation to OS and PFS. HCV RNA levels were measured by TaqMan PCR and by genotype. Results: Of 356 pts, 83 were HCV+ with more Black/African American (25/50 = 50%) vs. White (54/239 = 23%) or other race groups (4/67 = 6%) (p < 0.0001). HCV titer data were available on 54 pts (S: 28, DO+S: 26). At baseline, 12 pts (S: 7, DO+S: 5) were HCV-UN, and post-baseline HCV TL did not significantly differ between treatment arms; one patient in each arm went from detectable (HCV-D) to HCV-UN. Post-baseline, 40 pts were HCV-D vs. 14 who were HCV-UN (S+DO: 8, S: 6 pts). Except for the two pts who became HCV-UN, baseline HCV-D vs. HCV-UN titers was similar to that status post-baseline. PFS and OS between HCV-D and HCV-UN both at baseline and post-baseline are delineated in the table. Conclusions: We observed that S did not influence HCV TL. Pts treated with DO+S vs. S had worse PFS if they had HCV-UN, and further that higher levels of HCV titers at baseline were associated with significantly improved PFS. Given the small sample size, these findings warrant further prospective evaluation. Support: U10CA180821, U10CA180882, U24CA196171; Bayer, Bristol-Myers-Squibb, and Sanofi. https://acknowledgments.alliancefound.org . Clinical trial information: NCT01015833. [Table: see text]
Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia
Li, Shuangyue , Lu, Ying , Liu, Hsiao‐Chuan , Gang, Eun Ji , Le, Jing , Qian, S. B., Tang, Shanhao , Si, Ting, Pei, Renzhi , Li, Shuang-Yue , Qian, Su-Ying

Mayo Clinic

Leukemia & Lymphoma | January 15, 2021 | Volume: 62 | Issue: 5 | Pages: 1267-1270

10.1080/10428194.2020.1856832 | PMID 33439058 Get It

Renovascular Disease Induces Senescence in Renal Scattered Tubular-Like Cells and Impairs Their Reparative Potency
Chen, Xiao-Jun , Kim, Seo Rin , Jiang, Kai , Ferguson, Christopher M. , Zhu, Xiang-Yang, Eirin, Alfonso , Lerman, Lilach O. , Eirin, Alfonso , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

Hypertension | January 4, 2021 | Volume: 77 | Issue: 2 | Pages: 507-518

10.1161/hypertensionaha.120.16218 | PMID 33390051 Get It

Scattered tubular-like cells (STCs), dedifferentiated renal tubular epithelial cells, contribute to renal self-healing, but severe injury might blunt their effectiveness. We hypothesized that ischemic renovascular disease (RVD) induces senescence in STC and impairs their reparative potency. CD24+/CD133+ STCs were isolated from swine kidneys after 16 weeks of RVD or healthy controls. To test their reparative capabilities in injured kidneys, control or RVD-STC (5×10 5 ) were prelabeled and injected into the aorta of 2 kidneys, 1-clip (2k,1c) mice 2 weeks after surgery. Murine renal function and oxygenation were studied in vivo 2 weeks after injection using micro-magnetic resonance imaging, and fibrosis, tubulointerstitial injury, capillary density, and expression of profibrotic and inflammatory genes ex vivo. STC isolated from swine RVD kidneys showed increased gene expression of senescence and senescence-associated secretory phenotype markers and positive SA-β-gal staining. Delivery of normal pig STCs in 2k,1c mice improved murine renal perfusion, blood flow, and glomerular filtration rate, and downregulated profibrotic and inflammatory gene expression. These renoprotective effects were blunted using STC harvested from RVD kidneys, which also failed to attenuate hypoxia, fibrosis, tubular injury, and capillary loss in injured mouse 2k,1c kidneys. Hence, RVD may induce senescence in endogenous STC and impair their reparative capacity. These observations implicate cellular senescence in the pathophysiology of ischemic kidney disease and support senolytic therapy to permit self-healing of senescent kidneys.
Association of sleep-disordered breathing and wound healing in patients with diabetic foot ulcers
Chen, Lihong , Ma, Wanxia, Covassin, Naima , Zha, Panpan , Wang, Chun , Gao, Yun , Tang, Weiwei , Lei, Fei , Tang, Xiangdong , Tang, Xiangdong , Chen, Dawei , Ran, Xingwu

Mayo Clinic

Journal of Clinical Sleep Medicine | December 31, 2020 | Volume: 17 | Issue: 5 | Pages: 909-916

10.5664/jcsm.9088 | PMID 33382033 Get It

Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial
Zhou, Chenyun , Lok, U‐Wai , Tang, Shanshan , Taylor, Ann, Eckert, Deborah J., Chen, Shigao , Camilleri, Michael , Eckert, Deborah, Camilleri, M , Lok, U-Wai , Wang, Xiao Jing, Gong, Ping , Huang, Chengwu

Mayo Clinic

JGH Open | December 30, 2020 | Volume: 5 | Issue: 2 | Pages: 193-198

10.1002/jgh3.12464 | PMID 33553655 Get It

AbstractBackground and AimLiraglutide, a long‐acting GLP‐1 analog, is approved for the treatment of obesity with improvements in fasting blood glucose, hemoglobin A1c, and cardiovascular health. Our aim was to measure the impact of liraglutide dose for obesity on hepatic steatosis measured by ultrasound.MethodsA single‐center, randomized, double‐blind, placebo‐controlled pilot trial was undertaken in nondiabetic obese, otherwise healthy patients aged 18–65 years. Participants were randomly assigned to receive subcutaneous liraglutide (3.0 mg) or placebo over 16 weeks with dose escalation following US Food and Drug Administration guidelines. Both groups received standardized nutritional and behavioral counseling during the 16 weeks. Hepatic fat content was measured by ultrasound at baseline, 8 weeks, and 16 weeks as an attenuation coefficient (ACE). Effects of treatment were assessed using t‐test for the entire groups and for patient subgroup with baseline ACE >0.66 (indicating significant steatosis).ResultsAmong 30 patients (93% female) enrolled, 16 were randomized to placebo and 14 to liraglutide. Baseline body mass indices (BMIs) and average age were similar in the two groups. After 16 weeks, the liraglutide group had a significant improvement in steatosis ACE scores (−0.068 ± 0.02 vs −0.0077 ± 0.02 placebo, P = 0.05). Change in steatosis was positively correlated with change in BMI (R2 = 0.402, P = 0.0007). Within the liraglutide group, patients with baseline ACE >0.66 had improvement in ACE (−0.134 ± 0.03) compared to those without significant steatosis (−0.041 ± 0.02, P = 0.05).ConclusionsIn this pilot trial, liraglutide, 3.0 mg over 16 weeks, reduced hepatic steatosis; a reduction in hepatic steatosis is correlated with BMI reduction, and effects are particularly evident in those with a significant degree of steatosis by ultrasound imaging.
RBIO-03. HETEROGENEITY OF HUMAN PATIENT-DERIVED XENOGRAFTS GROWTH RATES RESPONSES TO THE RADIATED MICROENVIRONMENT
zhang, Jibo, Olson, Ian , Tang, Zhi , Sananikone, Eliot F., Dong, Anqin, Warrington, Arthur E. , Chen, Jincao , Ikram, Samar, Burma, Sandeep , Carlstrom, Lucas P. , Rahman, Masum , Rajani, Karishma , Gupta, Kshama, Liu, Libo, Dong, Anqin Dong, Rodriguez, Moses , Schroeder, Mark A. , Sarkaria, Jann N. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii192-ii192

10.1093/neuonc/noaa215.803 Get It

Abstract BACKGROUND Radiotherapy, combined with surgical resection and chemotherapy, remains a first-line treatment for infiltrative gliomas. However, these tumors are not surgically curable, and often recur, even within the prior radiation field, and may demonstrate a more aggressive phenotype. Importantly, high grade gliomas display diverse molecular phenotypes, and whether this genetic variability leads to divergent behaviour in the radiated tumor microenvironment is unknown. Herein, we characterize the effects of the irradiated brain microenvinroment on nine additional unique GBM cell lines to better understand the nuances of how tumor molecular phenotypes influence cellular dynamics. METHODS Female athymic nude mice were randomly divided into cranial radiation (15 Gy) and non-radiated groups. Mice then underwent intracranial implantation with one of the selected patient-derived xenograft (PDX) GBM cell lines (GBM 6, 10, 12, 39, 46, 76, 123, 164, 196; total n=8-15, per group, per line). Kaplan-Meyer (K-M) and log-rank tests were performed to compare the survival between irradiated and non-irradiated groups. RESULT Of nine previously untested human GBM lines, we found that five demonstrated shorter survival in the pre-radiated brain (GBM 6, 46, 76, 164, 196). However, two lines yielded prolonged survival in the pre-radiated brain (GBM 10, 12); GBM 39, 123 whose rate of growth was not impacted by the radiated brain. CONCLUSION These results highlight the likely critical impact of the irradiated microenvironment on tumor behaviour, yet illustrate that different tumors may exhibit opposing responses. Although further evaluation will be needed to understand mechanisms of divergent behavior, our data suggest the increased rate of growth in the radiated microenvironment may not apply to the fastest-growing tumor lines, which could instead demonstrate a paradoxical response.
Renovascular Hypertension Induces Myocardial Mitochondrial Damage, Contributing to Cardiac Injury and Dysfunction in Pigs With Metabolic Syndrome
Nargesi, Arash Aghajani , Farah, Mohamed C, Zhu, Xiang-Yang, Zhang, Lei , Jordan, Kyra L., Saadiq, Ishran M. , Lerman, Lilach O. , Eirin, Alfonso , Eirin, Alfonso , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

American Journal of Hypertension | December 2, 2020 | Volume: 34 | Issue: 2 | Pages: 172-182

10.1093/ajh/hpaa202 | PMID 33277650 Get It

Abstract BACKGROUND Renovascular hypertension (RVH) often manifest with metabolic syndrome (MetS) as well. Coexisting MetS and hypertension increases cardiovascular morbidity and mortality, but the mechanisms underlying cardiac injury remain unknown. We hypothesized that superimposition of MetS induces myocardial mitochondrial damage, leading to cardiac injury and dysfunction in swine RVH. METHODS Pigs were studied after 16 weeks of diet-induced MetS with or without RVH (unilateral renal artery stenosis), and Lean controls (n = 6 each). Systolic and diastolic cardiac function were assessed by multidetector CT, and cardiac mitochondrial morphology (electron microscopy) and myocardial function in tissue and isolated mitochondria. RESULTS Body weight was similarly higher in MetS groups vs. Lean. RVH groups achieved significant stenosis and developed hypertension. Mitochondrial matrix density and adenosine triphosphate production were lower and H2O2 production higher in RVH groups vs. Lean and MetS. Lean + RVH (but not MetS + RVH) activated mitophagy, which was associated with decreased myocardial expression of mitophagy-related microRNAs. MetS groups exhibited higher numbers of intermitochondrial junctions, which could have prevented membrane depolarization/activation of mitophagy in MetS + RVH. Cardiac fibrosis, hypertrophy (increased left ventricular muscle mass), and diastolic function (decreased E/A ratio) were greater in MetS + RVH vs. Lean + RVH. CONCLUSIONS MetS+RVH induces myocardial mitochondrial damage and dysfunction. MetS + RVH failed to activate mitophagy, resulting in greater cardiac remodeling, fibrosis, and diastolic dysfunction. Mitochondrial injury and impaired mitophagy may constitute important mechanisms and therapeutic targets to ameliorate cardiac damage and dysfunction in patients with coexisting MetS and RVH.
Insights from Twitter about novel COVID-19 symptoms
Krittanawong, Chayakrit , Narasimhan, Bharat , Narasimhan, Harish , Tang, W.H. Wilson , Tang, W H Wilson , Virk, Hafeez Ul Hassan , Wang, Zhen

Mayo Clinic

European Heart Journal - Digital Health | November 30, 2020 | Volume: 1 | Issue: 1 | Pages: 4-5

10.1093/ehjdh/ztaa003 | PMID 34192272 Get It